Ravulizumab: Characterization and quantitation of a new C5 inhibitor using isotype specific affinity purification and high-resolution mass spectrometry
Introduction: Ravulizumab (RAVUL) is a new complement inhibitor, with a difference of 4 amino acids in the heavy chain from a predecessor compound, eculizumab (ECUL). Objectives: First, to utilize mass spectrometry (MS) to characterize RAVUL and verify differences from its predecessor and, second, t...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier B.V.
2021
|
| Subjects: | |
| Online Access: | View Fulltext in Publisher |